Today, RBC Capital Markets Reiterates Sector Perform Rating for Concordia Healthcare Corp. (CXRX)

Today, RBC Capital Markets Reiterates Sector Perform Rating for Concordia Healthcare Corp. (CXRX)
Concordia Healthcare Corp. (NASDAQ:CXRX) (TSE:CXR)‘s stock had its “sector perform” rating restated by equities research analysts at RBC Capital Markets in a research report issued on Wednesday.

Several other equities analysts have also issued reports on the company. Canaccord Genuity lowered Concordia Healthcare Corp. to a “buy” rating and set a $10.00 target price for the company. in a research report on Friday, September 16th. TD Securities lowered Concordia Healthcare Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. CIBC lowered Concordia Healthcare Corp. from a “sector perform” rating to an “underperform” rating and set a $7.80 target price for the company. in a research report on Monday, August 15th. Goldman Sachs Group Inc. restated a “neutral” rating on shares of Concordia Healthcare Corp. in a research report on Tuesday, September 27th. Finally, Zacks Investment Research lowered Concordia Healthcare Corp. from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 17th. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $28.53.

Concordia Healthcare Corp. (NASDAQ:CXRX) opened at 2.46 on Wednesday. The company’s market cap is $125.50 million. The company’s 50-day moving average is $3.49 and its 200 day moving average is $13.70. Concordia Healthcare Corp. has a 12 month low of $1.69 and a 12 month high of $44.00.

Concordia Healthcare Corp. (NASDAQ:CXRX) last announced its quarterly earnings data on Monday, November 7th. The company reported $0.69 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.05 by $0.36. The firm had revenue of $185.50 million for the quarter, compared to the consensus estimate of $206 million. Concordia Healthcare Corp. had a positive return on equity of 22.81% and a negative net margin of 81.40%. The business’s revenue for the quarter was up 99.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.46 earnings per share. Equities analysts forecast that Concordia Healthcare Corp. will post $4.19 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP purchased a new position in Concordia Healthcare Corp. during the second quarter worth $571,000. Citigroup Inc. boosted its stake in shares of Concordia Healthcare Corp. by 18.5% in the second quarter. Citigroup Inc. now owns 8,976 shares of the company’s stock worth $184,000 after buying an additional 1,401 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Concordia Healthcare Corp. by 0.6% in the second quarter. ProShare Advisors LLC now owns 37,975 shares of the company’s stock worth $818,000 after buying an additional 224 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Concordia Healthcare Corp. by 9.1% in the second quarter. Vanguard Group Inc. now owns 715,117 shares of the company’s stock worth $15,404,000 after buying an additional 59,893 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Concordia Healthcare Corp. during the second quarter worth about $2,383,000. 27.87% of the stock is owned by hedge funds and other institutional investors.

Concordia Healthcare Corp. Company Profile

Related posts

Leave a Comment